Comparison of the effectiveness, safety and tolerability of Perampanel and Levetiracetam as monotherapy in Chinese patients with focal‐onset seizures: A single‐center, ambispective, open‐label, real‐world observational study

This study compared the effectiveness and safety of PER and LEV as monotherapy in Chinese patients with focal-onset seizures (FOS), in which 70 patients receiving PER monotherapy and 77 patients receiving LEV monotherapy were enrolled. Compared with LEV, PER had significantly higher seizure-freedom rates (SFRs) at 6 and 12 months and a non-significant trend of higher SFR at 24 months. The two treatments had comparable retention rates. Chinese patients with FOS receiving PER monotherapy were more likely to achieve seizure freedom and had a higher incidence of dizziness than LEV.